伊宁意外怀孕69天怎么办(伊宁妇科检查去哪) (今日更新中)

HONG KONG, July 19 (Xinhua) -- A gene controlled by male hormone was critical for the growth of liver tumor, leading to a higher incidence of the disease in men than in women, according to the Chinese University of Hong Kong which made the results public on Tuesday.There is a significant gender bias in liver cancer incidence. In Hong Kong, men are three times more likely to develop liver cancer than women. Such phenomenon prompted researchers from the university to carry out a genomic location analysis in liver cancer cells starting from 2008.The researchers discovered, out of 17,000 human genes, that a gene called Cell Cycle-Related Kinase (CCRK) was directly controlled by androgen receptor. They further found that CCRK was critical for the induction of signaling pathway leading to abnormal liver cell growth and tumor formation.The results also reveal that 70 percent of patients with liver cancer were found to produce high levels of CCRK. More importantly, these patients were more likely to have late-stage cancers and lived shorter than those with low CCRK level.Using mouse models, the researchers found that either lowering the level or blocking the signaling pathway of CCRK in liver cancer cells could significantly reduce the tumor growth rate.The study has validated that CCRK is an important gene that has potential to cause liver cancer and the gene can be tested as a new targeted therapy in future.Vice-Chancellor of the university Joseph Sung, who is also team leader of the research project, said the results explained why men have a higher risk of liver cancer than women and helped push ahead with the development of a novel treatment of the disease.The above study results were published online in July in Journal of Clinical Investigation.

WASHINGTON, June 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Monday unveiled in a report a new strategy to meet the challenges posed by rapidly rising imports of FDA- regulated products and a complex global supply chain.The report, titled "Pathway to Global Product Safety and Quality," calls on the agency to transform the way it conducts business and to act globally in order to promote and protect the health of U.S. consumers.According to the report, the FDA will partner with its counterparts worldwide to create global coalitions of regulators focused on ensuring and improving global product safety and quality. The coalitions of regulators will develop international data information systems and networks, and increase the regular and proactive sharing of data and regulatory resources across world markets.The FDA will build in additional information gathering and analysis capabilities with an increased focus on risk analytics and information technology. It increasingly will leverage the efforts of public and private third parties and industry and allocate FDA resources based on risk."FDA regulated imports have quadrupled since 2000. The FDA and our global regulatory partners recognize this new reality and realize we must work proactively and collaboratively to address the challenges we face," FDA Commissioner Margaret Hamburg said in a statement. "The FDA must further collaborate and leverage in order to close the gap between our import levels and our regulatory resources. This report is an important step in ensuring we are able to fulfill our critical public health mission."

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

NAIROBI, Aug. 18 (Xinhua) -- The World Health Organization (WHO) on Thursday decried increased number of confirmed cholera cases in the Somalian capital Mogadishu, and growing reports of acute watery diarrhea in Kismayo and other crowded urban centers, saying an urgent multi-sector response to contain the spread of this highly contagious disease is being mounted.The UN health agency said has confirmed cholera in Banadir, Bay, Mudug and Lower Shabelle regions and the number of acute watery diarrhea cases has increased dramatically in the last few months.WHO Representative for Somalia Marthe Everard said combination of poor sanitation conditions, a shortage of safe water, overcrowding and high malnutrition rates, creates the perfect combination for infectious diseases, such as cholera and pneumonia, to spread and increase the number of deaths. "For the last few years, a network of health workers reporting to the early warning system is in place, however they report through a health facility or mobile clinic. Yet the large numbers of displaced people in Mogadishu are making it more difficult to record the various diseases," Everard said in a statement issued in Nairobi. "We urgently need more mobile clinics that will provide basic health care services to the many displaced and who will strengthen the reporting on new outbreaks. This is critical to our response and our ability to save lives."According to WHO, about seventy-five percent of all cases of acute watery diarrhea are children under the age of five.Since January this year, 4,272 cases of acute watery diarrhea/ cholera have been reported in Banadir Hospital in Mogadishu alone. However, at this stage most of the cholera cases in the various regions are contained and under control. "Our major concern is to monitor and detect new disease outbreaks in the many informal settlements set up by internally displaced people in and around Mogadishu", says Everard.Although cholera is endemic in the country, the last major cholera outbreak was in 2007 with an estimated 67,000 cases.WHO said recent efforts to cholrinate the water supply of Mogadishu, along with efforts to improve hygiene and sanitation have prevented a serious outbreak but with the large influx of some 100,000 people alone this year into Mogadishu, bringing the total number of IDPs in the capital to an estimated 470,000, many are living in overcrowded settlements, there is an acute shortage of safe water and adequate sanitation. "There is no need for a child to die of diarrhea, yet this is tragic reality for a Somali child, who is acutely malnourished. It is a lethal combination." said Rozanne Chorlton, UNICEF Representative for Somalia. "These types of diseases can be prevented and treated quickly, but to save children's lives we need to make sure safe water, sanitation and hygiene along with early access to primary health care, are an integral part of our emergency response."WHO said partners in the health and water and sanitation sectors are currently preparing for a potential 100,000 cholera cases including 80,000 moderate cases and 20,000 severe cases.Emergency diarrheal disease kits made up of medical supplies such as syringes, infusions, and oral rehydration fluids (ORS), already prepositioned by UNICEF and WHO have been sent to 13 hospitals.An additional 200 diarrheal disease kits, each able to treat 100 severe cases and 400 moderate cases are being procured and should be in Southern Somalia in the next few weeks, it said.In addition, WHO said, the case management of severe dehydration with and without malnutrition is being strengthened and focus is now on mobilizing a network of already trained community health promoters to move from door to door with health hygiene education messages. "Health posts will be stocked with essential medicines and ORS to identify and promptly treat patients. Many of Southern Somalia' s rural areas and urban centers rely on shallow wells, which unless protected or treated with chlorine can serve as the perfect breeding ground for water borne diseases," it said.To respond to this threat and prevent a major outbreak, the UN health agency said partners in the water, sanitation and hygiene sector are scaling up their actions to target 1.5 million people across high risk areas of the south.Supplies of chlorine and essential items for hygiene and household treatment and storage of water are being distributed.Already 217 water sources are being chlorinated and 58 water point outlets benefitting 483,200 residents and internally displaced people in Mogadishu.In addition, household hygiene supplies, including water purification tablets, soap and buckets, enough for 48,000 families, are being distributed at existing feeding centers for malnourished children.Campaigns to educate families about the treatment of drinking water, safe disposal of waste and encourage hand washing with soap will also be scaled up in high risk communities.As part of the updated 2011 UN Consolidated Appeal for Somalia, an estimated 80 million U.S. dollars is needed for the health sector and 78 million dollars is required for the water, sanitation and hygiene sector.So far, each sector has respectively raised 30 percent and 37 percent of the required money.

来源：资阳报